EA201891340A1 - Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек - Google Patents

Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек

Info

Publication number
EA201891340A1
EA201891340A1 EA201891340A EA201891340A EA201891340A1 EA 201891340 A1 EA201891340 A1 EA 201891340A1 EA 201891340 A EA201891340 A EA 201891340A EA 201891340 A EA201891340 A EA 201891340A EA 201891340 A1 EA201891340 A1 EA 201891340A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
deoxy
combination
fukoza
fluor
Prior art date
Application number
EA201891340A
Other languages
English (en)
Russian (ru)
Inventor
Шира Гардай
Чэ-Леунг Ло
Питер Сентер
Николь Окили
Джессика Филд
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201891340A1 publication Critical patent/EA201891340A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201891340A 2015-12-04 2016-12-02 Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек EA201891340A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
EA201891340A1 true EA201891340A1 (ru) 2018-11-30

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891340A EA201891340A1 (ru) 2015-12-04 2016-12-02 Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек

Country Status (13)

Country Link
US (1) US20180353524A1 (enExample)
EP (1) EP3383404A4 (enExample)
JP (1) JP6906520B2 (enExample)
KR (1) KR20180086233A (enExample)
CN (1) CN108289903B (enExample)
AU (1) AU2016362993A1 (enExample)
BR (1) BR112018011261A2 (enExample)
CA (1) CA3005997A1 (enExample)
EA (1) EA201891340A1 (enExample)
IL (1) IL259479B (enExample)
MX (1) MX385283B (enExample)
SG (2) SG11201804263PA (enExample)
WO (1) WO2017096274A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
MA50865A (fr) * 2017-06-07 2020-04-15 Seattle Genetics Inc Lymphocytes t à fucosylation de surface réduite et procédés de production et d'utilisation de ceux-ci
US11911404B2 (en) * 2017-10-13 2024-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune surveillance in melanoma
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
US12642809B2 (en) 2019-08-16 2026-06-02 H. Lee Moffitt Cancer Center And Research Institute Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
US20240238318A1 (en) * 2021-05-06 2024-07-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака

Also Published As

Publication number Publication date
SG11201804263PA (en) 2018-06-28
US20180353524A1 (en) 2018-12-13
CA3005997A1 (en) 2017-06-08
EP3383404A1 (en) 2018-10-10
JP6906520B2 (ja) 2021-07-21
SG10202005298RA (en) 2020-07-29
IL259479A (en) 2018-07-31
AU2016362993A1 (en) 2018-07-12
BR112018011261A2 (pt) 2018-11-21
CN108289903B (zh) 2021-08-03
IL259479B (en) 2022-03-01
MX2018006674A (es) 2018-11-09
CN108289903A (zh) 2018-07-17
EP3383404A4 (en) 2019-07-31
MX385283B (es) 2025-03-18
KR20180086233A (ko) 2018-07-30
WO2017096274A1 (en) 2017-06-08
JP2019501145A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
IL254719A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
PH12017500881B1 (en) Aurora a kinase inhibitor
EA201591509A1 (ru) Ингибиторы cdc7
MX2017013802A (es) Métodos para tratar el cáncer.
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
GB2541571A (en) Pharmaceutical compositions
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
EA201991818A1 (ru) Лечение рака
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2016009663A (es) Derivados de icariina.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX390320B (es) Farmaco de combinacion.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EA201692534A1 (ru) Способы лечения гипотонии
IL272379A (en) Methods of treating cancer by inhibiting setd2